Yahoo Finance 
Yahoo Finance Plus Mike Francesa unveils his own app
Sports radio host Mike Francesa is rolling out his very own app, Mike's On. But, it will cost you. Users can pay $8.99 a month or $98.99 for a one-year subscription, to get more Francesa than WFAN has to offer.
Sports radio host Mike Francesa is rolling out his very own app, Mike's On. But, it will cost you. Users can pay $8.99 a month or $98.99 for a one-year subscription, to get more Francesa than WFAN has to offer.
Stephen Schwartzman, worth $42 billion and at the head of a firm managing almost $1 trillion, says social media is what doomed the bank.
GSK plc (NYSE: GSK) and Scynexis Inc (NASDAQ: SCYX) have entered into an exclusive license agreement for Brexafemme (ibrexafungerp tablets). The FDA approved the antifungal for vulvovaginal candidiasis (VVC) and reduced the incidence of recurrent VVC (RVVC). This exclusive agreement gives GSK rights to commercialize Brexafemme for VVC and RVVC while continuing to develop ibrexafungerp, which is in phase 3 trials for potentially treating invasive candidiasis (IC), which affects the blood or inter
Investors looking for alpha in an uncertain market environment could do worse than following in the footsteps of legendary stock pickers and probably none can match Warren Buffet’s reputation. Not for nothing the “Oracle of Omaha” is considered one of the all-time greats and for nearly 60 years, between 1965 and 2022, his Berkshire Hathaway firm’s returns have doubled those of the S&P 500. So, it’s definitely worth nosing through Buffett’s portfolio to see which stocks he currently holds. And wh
The Oracle of Omaha never saw a future in cryptocurrency.
The Nasdaq topped 12,000 as the market rallied ahead of the PCE inflation report. The IRS will likely cut EV credits for Tesla's entry-level Model 3.
Here are some of today's after-hours movers.
My wife and I are 70 years old. We've paid off everything, including the house. Between my pension of $29,000 and Social Security, we're getting a gross of $99,000 a year in income, which is more than enough. Our current … Continue reading → The post Ask an Advisor: We Are 70 Years Old, Have $99K in Retirement Income, a $1.4M IRA and Other Investments. Is It Too Late to Convert to a Roth? appeared first on SmartAsset Blog.
For most people, it will be little or no problem to retire at age 65 if they have $2.5 million in savings. This amount of capital invested prudently is likely to provide sufficient income for a lifestyle comfortable enough to … Continue reading → The post Is $2.5 Million Enough to Retire at 65? appeared first on SmartAsset Blog.
The firm said it was relocating “immediately” from Washington after the state’s supreme court cleared the way for a capital gains tax on individuals.
'The benefits are great on paper, but often don’t exist in reality due to inconsistent scheduling.'
97% of companies think spying on their remote workers makes them more productive. But many employees end up getting fired for it—or quitting.
A Citigroup preferred stock yields about 10%, an unusually good deal. Bank regulations passed in the wake of the financial crisis disallowed trust preferred as a component of Tier 1 bank capital but grandfathered the Citigroup issue. This gives Citigroup an incentive to keep the preferred outstanding.
Recently, Zacks.com users have been paying close attention to ZIM (ZIM). This makes it worthwhile to examine what the stock has in store.
Rule changes living rent-free in your mind? Perhaps it's time for a more passive approach.
The salaries offered to U.S. accountants and auditors last year climbed at their quickest pace in recent years, but industry observers say increasing pay alone may not be enough to remedy a national shortage of accountants.
The Zacks Tobacco industry players are seeing low cigarette sales and commodity cost inflation. However, a focus on low-risk products and solid pricing bode well for Philip Morris (PM), Altria Group (MO) and Turning Point Brands (TPB).
The semiconductor maker brings forward timelines for production of next-generation data-center chips.
T. Rowe Price fixed-income manager Cheryl Mickel identifies the best spots to park short-term cash, how to navigate the banking sector, and where the Federal Reserve may be going next.
It’s been a good week for investors of Pyxis Oncology (NASDAQ:PYXS), to say the least. Over the past 4 sessions Pyxis shares have gained 170%, bringing the year-to-date haul to a mighty 340%. This biotech micro-cap is backed by Pfizer, which is largely responsible for the recent rally. According to a recent SEC filing, the pharma giant loaded up on 1,811,594 PYXS shares earlier this month for a total sum of $5 million, paying $2.76 per share. This raised Pfizer’s ownership in Pyxis to 5,952,263